Oxford BioMedica (OXBDF) Stock Price, News & Analysis

Company Overview

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and development of new gene therapeutic product candidates. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, and adenoviral vectors. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.

Key Stats

• Today's Range: $6.72 to $6.72
• 50-Day Range: $4.23 to $6.72
• 52-Week Range: $3.15 to $6.72
• Volume: 525 shs
• Average Volume: 524 shs
• Market Capitalization: $711.82 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

OXBDF Stock Analysis - Frequently Asked Questions

How have OXBDF shares performed this year?

Oxford BioMedica's stock was trading at $5.3950 at the beginning of 2025. Since then, OXBDF stock has increased by 24.5% and is now trading at $6.7178.

How do I buy shares of Oxford BioMedica?

Shares of OXBDF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 8/18/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:OXBDF
• Previous Symbol: NASDAQ:OXBDF
• CIK: N/A
• Web: www.oxfordbiomedica.co.uk
• Phone: 44-18-6578-3000
• Fax: N/A
• Employees: 891
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $111.34 million
• Price / Sales: 6.39
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.01 per share
• Price / Book: 6.65

Miscellaneous

• Outstanding Shares: 105,960,000
• Free Float: N/A
• Market Cap: $711.82 million
• Optionable: Not Optionable
• Beta: 1.08